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Background: There is a high unmet need for effective treatments for patients with squamous non-small cell
lung cancer (NSCLC). Eli Lilly and Company is conducting a phase III, randomized, multicenter, open-label study
of gemcitabine plus cisplatin plus necitumumab (GC + N) versus gemcitabine plus cisplatin (GC) for the first-line
treatment of patients with stage IV squamous NSCLC. Given GC is not the only treatment commonly used for
the treatment of squamous NSCLC, this study was designed to compare the survival, toxicity, and quality of life
outcomes of current treatment strategies for squamous NSCLC in the first-line setting.
Methods/Design: A systematic review and meta-analysis (including indirect comparisons) of treatments used in
squamous NSCLC will be conducted to assess the clinical efficacy (overall and progression-free survival), health-related
quality of life (HRQoL), and safety (grade 3–4 toxicity) of GC + N compared to other treatments used in squamous
NSCLC. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines will be followed for
all aspects of this study. A systematic literature review will be conducted to identify randomized controlled trials
evaluating chemotherapy treatment in first-line NSCLC. Eligible articles will be restricted to randomized controlled
trials (RCTs) among chemotherapy-naïve advanced NSCLC cancer patients that report outcome data (survival, toxicity,
or quality of life) for patients with squamous histology. Following data extraction and validation, data consistency and
study heterogeneity will be assessed. A network meta-analysis will be conducted based on the available hazard ratios
for overall and progression-free survival, odds ratios for published toxicity data, and mean difference of HRQoL scales.
Sensitivity analyses will be conducted.
Discussion: This is a presentation of the study protocol only. Results and conclusions are pending completion of this
study.
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Lung cancer is the leading cause of cancer-related deaths
worldwide, accounting for 1.3 million deaths annually [1].
It is defined as cancer that forms in the tissues of the lung,
usually in the cells lining air passages, and is divided into
two main subtypes: small cell lung cancer (SCLC) and
non-small cell lung cancer (NSCLC). NSCLC is the pre-
dominant subtype form and accounts for about 85% of all
lung cancers [2]; it is further divided by cell histology into
adenocarcinoma, squamous cell carcinoma, and large-cell
carcinoma, with adenocarcinoma the currently predomin-
ant histology. Although the overall age-adjusted incidence
rates for lung cancer are declining in many developed na-
tions, lung cancer remains the leading cause of cancer-
related deaths worldwide with an overall 5-year survival
rate of about 15% [3], resulting in a significant disease bur-
den worldwide.
The treatment of lung cancer is based on the type
and stage of tumor, as well as the patient’s general med-
ical condition. For patients diagnosed with early stage
disease (i.e., stages I and II), surgery offers the best op-
tion for survival and cure. Adjuvant chemotherapy is in-
creasingly used in those with stage II disease and
occasionally for those with stage IB, depending on the size
of the tumor. For those with stage III lung cancer, chemo-
radiotherapy alone or in addition to surgery is used to
treat patients; however, while treatment is administered
with a curative intent, the 5-year survival for patients
with regional disease is approximately 26%, which de-
creases to 3.9% for patients with metastatic disease
[3]. Treatment for patients with advanced disease tends
to be palliative, although extension in survival may be
achieved. The standard first-line drug treatments for
advanced NSCLC, neoadjuvant, adjuvant, or chemora-
diotherapy, are generally based on the combination of a
second- or third-generation cytotoxic drug with a plat-
inum agent (cisplatin or carboplatin).
There are many drug therapies available for treatment
of NSCLC; however, not all current therapies are suit-
able for use in tumors of all histologies. The results of
clinical trials have indicated that drugs such as peme-
trexed have greater efficacy among patients with adeno-
carcinoma than those with other NSCLC histologies
(e.g., squamous cell carcinoma) [4]. Other newer agents,
such as bevacizumab, are indicated for adenocarcinoma
because of higher toxicities observed in patients with
squamous histology [5]. Drugs such as erlotinib and
gefitinib are not restricted by histology, but have greater
efficacy among patients with epidermal growth factor
receptor (EGFR) mutations [6,7]. The frequency of EGFR
mutations in patients with squamous cell carcinoma, as
opposed to those with adenocarcinoma, is very low
[8]. Therefore, histology-specific treatment options are
limited for patients with squamous cell carcinoma,which accounts for about 25% of all non-small cell
lung cancers [9].
There is thus a high unmet need for effective treat-
ments for patients with squamous NSCLC, as disease
burden is large and there is currently a lack of targeted
drug therapies for NSCLC squamous cell tumors. Eli
Lilly and Company is currently developing necitumumab
as a first-line treatment in patients with stage IV squamous
NSCLC. The current phase III study (ClinicalTrials.gov
identifier: NCT00981058) is a randomized, multicenter,
open-label study of gemcitabine-cisplatin chemotherapy
plus necitumumab (GC +N) versus gemcitabine-cisplatin
(GC) chemotherapy alone in first-line treatment of patients
with stage IV squamous NSCLC. The target patient popu-
lation for this trial is comprised of male and female
patients with histologically or cytologically confirmed, ad-
vanced squamous NSCLC, previously untreated for meta-
static disease.
The purpose of this systematic literature review and
meta-analysis is to compare survival, toxicity, and quality
of life outcomes of current treatment strategies with
necitumumab among patients with squamous NSCLC.
Methods/Design
This systematic literature review and meta-analysis (in-
cluding indirect comparisons) will be conducted of treat-
ments used in squamous NSCLC to assess the clinical
efficacy, quality of life, and safety of GC +N compared
to other treatments used in squamous NSCLC. To
complete this objective, the following specific aims will
be pursued:
1. To conduct a systematic literature review of
randomized trials of all relevant treatments used for
the first-line treatment of advanced squamous
NSCLC;
2. To extract relevant data from the relevant published
literature;
3. To perform indirect and direct comparisons of





3.4 Quality of lifeSearch strategy
Searches will be conducted in PubMed, Ovid/MEDLINE,
and Embase using free text and controlled vocabulary
terms (MeSH). Studies published prior to 1995 will be
excluded as NSCLC histology was not clearly differenti-
ated at that time. Studies not published in English will
be excluded. Comparisons will be made across all regi-
mens and not just limited to “add-on” therapies. Tables 1,
Table 1 PubMed search strategy
PubMed search
Category Search Query Items found
Disease terms #1 “carcinoma, non small cell lung/drug therapy” [MeSH Terms] 11,135
Design terms #2 Randomized Controlled Trials as Topic [MeSH Major Topic] 12,361
#3 “randomized controlled trials as topic” [MeSH Terms] 85,095
#4 Random Allocation [MeSH Terms] 76,843
#5 double blind method [MeSH Terms] 118,616
#6 “controlled clinical trial” [Publication Type] 85,642
#7 “randomized controlled trial” [Publication Type] 344,749
#8 “clinical trials as topic” [MeSH Terms] 263,513
#9 “clinical trial” [Publication Type] 709,361
#10 ((#2 or #3 or (#4 and (#5 or #8 or #9)) or #6 or #7)) 509,729
#11 ((randomization and control and clinical and trial)) 10,468
#12 (((randomised and control and clinical and trial) or (randomized and control and clinical and trial))) 108,134
#13 ((((double or single or triple or treble) and (blind* or mask*) and (random*)))) 136,554
#14 (((random and allocat*) and control* and trial)) 4,775
#15 (#12 or #13 or #14) 214,899
#16 (#10 or #15) 527,440
#17 (#1 AND #16) 2,065
Exclusion terms #18 Case report [Title/Abstract] 195,029
#19 Review [Publication Type] 1,765,829
#20 Letter [Publication Type] 794,012
#21 “systematic review” [Title/Abstract] 39,341
#22 “clinical review” [Title/Abstract] 3,144
#23 (#18 OR #19 OR #20 OR #21 OR #22) 2,734,788
#24 (#17 NOT #23) 1,579
Year and language terms #25 ((#24) AND (“1995” [Date - Publication]: “2013” [Date - Publication])) AND English [Language] 1,217
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Ovid, and Embase, respectively.
The following is a list of the conference databases that
will be searched:
 American Association for Cancer Research, AACR
 American College of Radiation Oncology
 American Society for Radiation Oncology, ASTRO
 American Society of Clinical Oncology, ASCO
 Asia Pacific Lung Cancer Conference, APLCC
 Asia Pacific Oncology Summit, APOS
 Asian Oncology Summit, AOS
 Atualizacoes em Oncologia
 Australian Lung Cancer Conference, ALCC
 Austrian Society of Haematology and Oncology,
ASHO
 The Association for Cancer Surgery, BASO
 Biennial Congress of the European Association for
Cancer Research, EACR British Thoracic Oncology Group Conference,
BTOG
 Clinical Oncology Society of Australia, COSA
 Cancer Symposium of the Society of Surgical
Oncology, CSSSO
 Chicago Supportive Oncology Conference, CSOC
 Clinical Interventional Oncology, CIO
 Congres National de la Societe Francaise de
Radiotherapie Oncologique, SFRO
 Congress of the European Society for Medical
Oncology, ESMO
 Congress of the European Society of Surgical
Oncology, ESSO
 Congress of the International Society of Oncology
and Biomarkers, ISOBM
 Educational Cancer Convention Lugano of the
European School of Oncology, ECCLU
 European Lung Cancer Conference, ELCC
 European Multidisciplinary Cancer Congress
Table 2 Embase search strategy
Embase search
Category Search Query Hits
Design terms #1 “randomized controlled trial (topic)”/exp 37,931
#2 “randomized controlled trial”/exp 337,523
#3 “randomization”/exp 61,698
#4 “double blind procedure”/exp 115,032
#5 [controlled clinical trial]/lim 511,199
#6 [randomized controlled trial]/lim 337,523
#7 “clinical trial”/exp 961,450
#8 “clinical trial (topic)”/exp 73,222
#9 #1 OR #2 OR #3 OR #4 OR #5 OR #6 1,088,520
#10 singl*: ab,ti OR doubl*: ab,ti OR treb*: ab,ti OR tripl*: ab,ti AND (blind*: ab,ti OR mask*: ab,ti) 174,394
#11 “placebo”/exp 236,244
#12 random* AND (clinical OR control*) AND trial OR (placebo* AND
(“randomly allocated” OR (allocated AND random*)))
504,649
#13 (#7 OR #8) AND (#10 OR #11 OR #12) 513,722
#14 #9 OR #13 705,098
Exclusion terms #15 [conference review]/lim 3,863
#16 “case report”:ab,ti 256,868
#17 [review]/lim 2,026,389
#18 [letter]/lim 827,115
#19 “phase 1 clinical trial”/exp 24,619
#20 [short survey]/lim OR “historical article”: ab,ti 514,714
#21 “systematic review”: ab,ti 78,920
#22 “clinical review”: ab,ti 3,904
#23 #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 3,628,070
#24 #14 NOT #23 424,301
Rx terms #25 “drug therapy”/exp/mj 574,153
#26 “treatment response”/exp/mj 2,763
#27 “treatment outcome”/exp/mj 28,936
#28 “drug efficacy”/exp/mj 153,753
#29 “outcome assessment”/exp/mj 9,603
#30 chemothera* OR (“drug”/exp/mj AND thera*) OR antineoplastic* OR palliat* OR standar* NEAR/2
care OR support* NEAR/2 care OR “best supportive care” OR best?support* NEXT/2 care
1,895,030
#31 “radiotherapy”/exp 367,367
#32 #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 2,609,134
#33 #23 AND #31 88,937
Disease terms #34 ((lung$ OR pulmon$) NEAR/5 (adenocarcinom$ OR squamous OR “large cell” OR “non-small cell”)): ab,ti 44,817
#35 “lung non small cell cancer”/exp 52,027
#36 metastatic: ab,ti 181,820
#37 advanced: ab,ti 320,393
#38 stage 3: ab,ti 61
#39 “Stage 3”: ab,ti 8,708
#40 stage 4: ab,ti 32
#41 “stage 4”: ab,ti 5,270
#42 stage iii: ab,ti 30
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Table 2 Embase search strategy (Continued)
#43 “stage iii”: ab,ti 31,468
#44 stage iv: ab,ti 41
#45 “stage iv”: ab,ti 20,205
#46 “stage iii/iv”: ab,ti 6
#47 “stage iii/iv”: ab,ti 4,552
#48 “stage iiib/iv”: ab,ti 2
#49 “stage iii/iva”: ab,ti 1
#50 stage* iii: ab,ti 32
#51 stage* iii*: ab,ti 49
#52 stage* iv: ab,ti 41
#53 stage* iv*: ab,ti 52
#54 stage iii*: ab,ti 47
#55 stage iv*: ab,ti 46
#56 inoperable: ab,ti 12,989
#57 in* operable: ab,ti 13,465
#58 unresectable: ab,ti 15,735
#59 non* resectable: ab,ti 1,208
#60 late* stage: ab,ti 84
#61 late: ab,ti AND stage: ab,ti 41,346
#62 metast*: ab,ti OR advance*: ab,ti 900,959
#63 relaps* OR recurr* OR unresect* OR non?resect* OR in?operable OR non?operable
OR un?operable OR advanc* OR metasta* OR late NEAR/2 stage
1,895,338
#64 #34 OR #35 61,621
#65 #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49
OR #50 OR #51 OR #52 OR #53 OR #54 OR #55 OR #56 OR #57 OR #58 OR #59 OR #60 OR #61 OR #62 OR #63
1,943,775
#66 #64 AND #65 33,907
#67 #33 AND #66 2,689
Language and year #68 [1995–2013]/py AND [english]/lim 12,998,680
Final #69 #67 AND #68 2,901
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Oncology, EMCTO
 Hematology Oncology Pharmacy Association
Annual Meeting, HOPA
 International Conference and Exhibition on Cancer
Science and Therapy, IMPAKT
 International Conference of the Society for
Integrative Oncology
 International Lung Cancer Congress
 International Symposium on Targeted Anticancer
Therapies, TAT
 Italian Society of Surgical Oncology Conference
 Medical Oncology Group of Australia, MOGA
 Oncology Platform and Poster Presentation, CSM
2009
 Scientific Association of Swiss Radiation Oncology,
SASRO Scientific Meeting of the International Society for
Biological Therapy of Cancer
 Scientific Meeting of the Society for Immunotherapy
of Cancer, SITC
 Symposium of the International Society of Oncology
Pharmacy Practitioners
 UK Radiation Oncology Conference
 World Conference on Interventional Oncology,
WCIO
 World Congress on Cancer Science and Therapy
Eligibility assessment
To be eligible, published studies must meet the criteria
outlined in Table 4. Briefly, eligible articles must report
at least one of the following outcomes (overall survival,
progression-free survival, quality of life, or toxicity) for
patients with squamous NSCLC. Eligible articles must
Table 3 Ovid/MEDLINE search strategy
Ovid/MEDLINE search
Category Search Query Hits
Design terms #1 Randomized Controlled Trials as Topic/ 100,690
#2 Randomized Controlled Trial/ 382,290
#3 Random Allocation/ 80,788
#4 Double Blind Method/ 129,303
#5 controlled clinical trial.pt. 88,866
#6 randomized controlled trial.pt. 382,290
#7 Clinical Trial/ 499,767
#8 clinical trial.pt. 499,767
#9 Clinical Trials as Topic/ 173,590
#10 1 or 2 or 3 or 4 or 5 or 6 631,570
#11 7 or 8 or 9 602,541
#12 ((singl* or doubl* or treb* or tripl*) and (blind* or mask*)).ab,ti. 145,496
#13 Placebos/ 33,372
#14 ((random* and (clinical or control*) and trial) or (placebo* and (“randomly allocated” or
(allocated and random*)))).mp. [mp = title, abstract, original title, name of substance word,
subject heading word, keyword heading word, protocol supplementary concept,
rare disease supplementary concept, unique identifier]
457,488
#15 12 or 13 or 14 513,100
#16 11 and 15 264,991
#17 10 or 16 645,804
Disease terms #18 ((lung* or pulmon*) and (adenocarcinom* or squamous or “large cell” or “non-small cell”)).ab,ti. 59,093
#19 Carcinoma, Non-Small-Cell Lung/ 34,861
#20 (metastatic or advanced or stage or “stage 3” or stage4 or “stage 4” or stageIII or “stage III”
or StageIV or “Stage IV” or Stage?III or “Stage ?III” or Stage?IV or “Stage ?IV” or “StageIII/IV” or
“Stage III/IV” or “StageIII?/IV?” or “Stage III?/IV?” or “StageIII/StageIV” or “Stage III/Stage IV” or
“StageIII?/StageIV?” or “Stage III?/Stage IV?” or inoperable or in?operable or unresectable or
non?resectable or “late?stage” or (metast* or advance*)).ab,ti.
1,177,250
#21 18 or 19 66,533
#22 20 and 21 34,403
#23 17 and 22 3,600
Exclusion terms #24 case report.ab,ti. 201,610
#25 review.pt. 1,893,388
#26 letter.pt. 817,960
#27 Clinical Trial, Phase I.pt. 15,867
#28 Historical Article/ 298,058
#29 systematic review.ab,ti. 44,587
#30 clinical review.ab,ti. 3,354
#31 24 or 25 or 26 or 27 or 28 or 29 or 30 3,184,956
#32 23 not 31 2,702
Rx terms #33 drug therapy/ or treatment outcome/ or (“treatment” and “response”).ab,ti. or
(“drug” and “efficacy”).ab,ti. or outcome assessment/
1,014,086
#34 32 and 33 1,611
Final #35 limit 34 to yr = “1995 -Current” 1,464
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since 1995. Abstracts of all potentially eligible citations
will be reviewed and excluded if it can be definitivelystated that no eligibility criterion is met. All other publica-
tions will be considered potentially eligible. Full-text arti-
cles of all potentially eligible citations will be obtained and
Table 4 Eligibility criteria and screening matrix
Eligibility criteria
Patients Male or female patients with histologically or cytologicallyconfirmed squamous NSCLC
Study participants must have not received chemotherapy treatment prior to first-line chemotherapy
for NSCLC at the time of randomization in the study
Interventions The study assesses a chemotherapy treatment in each of the study arms
No limits are placed on the type of chemotherapy used
Outcomes One or more of the following outcomes must be quantitatively reported in the publication:
overall survival, progression-free survival, toxicity, or quality of life
At least one of the required outcome variables must be reported separately for patients with
advanced or metastatic (stage III/IV) NSCLC that is of squamous histology
Study design RCTs
Time frame 1995 to present
Ineligibility criteria
Interventions Not first-line treatment with first-line defined as patients with no prior exposure to chemotherapy
Radiation therapy in the absence of concurrent chemotherapy in any treatment group
Study design Review articles, news, editorials, commentaries
Time frame Publication date prior to 1995








Yes No Yes/No Need full text to determine the inclusion






Yes Yes Not possible case
No Yes Yes
Yes No No







No Yes Yes/No This may be multisite cancer study, need
full text to determine the inclusion
Yes No Yes/No Need full text to determine the inclusion
No No Noise in the search Need full text to determine the inclusion
Multiple cancers If mentions lung cancer Yes/No Need full text to determine the inclusion
If does not mention any specific tumor types Yes/No Need full text to determine the inclusion
If only mentions breast cancer or other
types and does not mention lung cancer
Noise in the search
Matrix for “not first-line treatment”
Condition Line of treatment to be considered Inclusion Comments
Naïve NSCLC patients 1st Yes
First- or front-line treatment 1st Yes




Chemo-naïve NSCLC patients 1st Yes
DeLozier et al. Systematic Reviews 2014, 3:102 Page 7 of 18
http://www.systematicreviewsjournal.com/content/3/1/102
Table 4 Eligibility criteria and screening matrix (Continued)
Second-line treatment 2nd No
(Rx)-resistant NSCLC patients 2nd No




If no clear information on line
of treatment
NA Yes/No Need full text to determine the inclusion
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both the abstracts and full-text articles will be assessed in-
dependently by two reviewers using the criteria and
screening matrix presented in Table 4. If the two reviewers
do not agree on the eligibility of an article, a third reviewer
will serve as the tie breaker. Systematic reviews and other
review articles will be scanned to ensure no eligible ran-
domized controlled trials (RCTs) are missed.
Data extraction and verification
In a process similar to that used for assessing eligibility,
two reviewers will independently extract the data ele-
ments listed in Table 5 from each eligible article. These
data are extensive and it is not expected, nor is it re-
quired, that all studies will report all data fields included.
However, attempts to collect as extensive of data as pos-
sible will be made to increase the potential range of sen-
sitivity and descriptive analyses. In addition to the data
extraction, two reviewers will also assess bias using the
Cochrane Risk of Bias Tool and will measure study qual-
ity using the Physiotherapy Evidence Database (PEDro)
scale (see the “Assessment of bias and study quality” sec-
tion). Data from both reviewers will be compared. If any
data element does not match, the reviewers will meet
and attempt to resolve the discrepancies. In cases of
non-resolution, a third reviewer will be consulted. All
rules and decision criteria used in the data resolution
process will be recorded for quality assurance and meth-
odological consistency purposes. To further ensure the
accuracy of the extracted data, a subset of 10% of all ex-
tracted articles will be verified by an individual not in-
volved in the data extraction process. In cases of error
detection, the full database will be reviewed to ensure
accuracy.
Analysis plan
A PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) diagram will be developed
based on the search strategy and eligibility assessment to
show the flow of included and excluded studies. The de-
scriptive statistics from each trial of patients with squa-
mous cell carcinoma will be included and described.
These variables will include treatment group, number of
patients, mean age (standard deviation), number andpercent male, number and percent with stage IV disease,
overall survival, progression-free survival, toxicity, and
quality of life.
A network diagram visually describing existing treat-
ments for squamous NSCLC will be created after all eli-
gible studies have been identified. However, some
publications may not present data in a format that al-
lows them to be included in the study despite otherwise
meeting eligibility criteria (e.g., mixed populations not
reported separately, mixed histologies not reported sep-
arately, mixed lines of therapy not reported separately).
In the case of a disconnected network resulting from the
absence of data for the appropriate patient population,
authors of such articles will be contacted and asked to
provide the needed data from their publications that
would enable connection to the studied network.
The primary purpose of this study is to perform indir-
ect and direct comparisons of GC +N versus all identi-
fied comparators for overall survival (OS) and
progression-free survival (PFS). Individual hazard ratios
(HR) or median time-to-event (median time) and 95%
confidence intervals (90% or 99% confidence intervals
will be converted to 95%) for overall survival will be in-
cluded in the network meta-analysis using a Bayesian
approach that ensures the preservation of randomization
in the network [10]. The HR will be used as the primary
unit of analyses to evaluate differences in effect size be-
tween treatment groups. Data for analysis will be ex-
tracted directly from the text of each eligible article,
calculated from data included in the text, or extrapolated
from the Kaplan-Meier plot according to the method of
Parmar and colleagues [11]. Graphs and figures will be
digitized using TechDig software and/or xyscan tool
(Debian, Inc) if necessary, and digitized values will be
extracted.
Heterogeneity will be explored by comparing the fixed
and random effects models to ensure that the network
has good properties. Additionally, heterogeneity will be
explored by visual inspection of forest plots. The
consistency assumption will be tested by examining net-
work diagrams to identify any closed “loops” where in-
consistencies can occur. When the network is complex
with multiarm trials, the “node-splitting” approach de-
fined by Dias and colleagues [12] will be used to identify
Table 5 Variables for data extraction
Arm-phase-period information by study arm and overall
Arm Unique arm number. Unique number for the treatment arm is
a grouping variable that is used to highlight which outcome is
in the same group of subjects
Integer, in case of sub-analysis arm use A.a format.
Placebo = 0, for sub-arm 0.1
Number of study arms 1, 2, 3
Open label versus blinded
Phase of study 1, 2, 3, or unknown
Objectives OS, PFS, RR, TPD, etc.
Patients randomized Number of patients randomized to the arm Number value
Arm description Description of the treatment arm usually includes the drug
name, dose, and frequency
e.g., methotrexate 10 mg QW (once a week)
Sub arm analysis Indicates if the analysis is in a subset of study arm Yes, NA. Use all in case of AE or dropout data
is reported for the randomized trial population
Arm comment Comment referring to the arm Comment in relevance to the understating of arm
or NA
Study phase Description of the specific phase within the overall study from
which the data is derived
Lead-in, active, follow-up
Study phase description Qualifies the “Study Phase” field with any additional
information deemed necessary or helpful for that arm
e.g., open-label follow-up
Phase duration Length of time of the study phase from which the data is
derived for the arm
Time
Phase duration unit Time unit for phase duration for the arm Units
Phase comment Comment concerning the study phase Any comment that is relevant to the understanding
of the phase or NA
Period Used if necessary to separate crossover periods within a
crossover trial
If the phase has multiple periods, the number of
the period. Integer in sequence, or NA
Period description Used to qualify the “Period” field with any additional
information deemed necessary or helpful
e.g., treatment A, titration, maintenance, NA
Period duration Length of time of the period in a study phase from which the
data is derived
Time, NA
Period duration unit Time unit for period duration Units, NA
Period comment Comment concerning the period Any comment that is relevant to the understanding
of the period or NA
Repository Description Data entry standards
Demographics and medical history information at baseline by study arm and overall—adjusted and unadjusted
Age Mean (or median) age in years of patient population or
treatment arm population
Age in years or NR if not mentioned specifically or
clearly in the trial
Percent female Percent of females in the patient population or treatment arm
population
Percent or NR if not mentioned specifically or
clearly in the trial
Weight Mean body weight of the patient or treatment arm population Weight in kg, normalize if needed or NR if not
mentioned specifically or clearly in the trial
Height Mean height of the patient or treatment arm population Height in cm, normalize if needed or NR if not
reported
BMI Mean body mass index of the treatment arm population BMI in kg/m2, normalize if needed or NR if not
reported in the trial
DBP Mean (or median) diastolic blood pressure mmHg
SBP Mean (or median) systolic blood pressure mmHg
Inclusion Description of treatment arm or sub-arm inclusion criteria
under the trial protocol
e.g., for sub-group females only, or NR if not
mentioned specifically or clearly in the trial
Exclusion Description of treatment arm or sub-arm exclusion criteria
under the trial protocol
e.g., for sub-group exclusion of females with
child-bearing potential, or NR if not mentioned
specifically or clearly in the trial
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Table 5 Variables for data extraction (Continued)
Ethnic white Percent of the ethnic population who are whites or Caucasian
in the trial
Percent or NR if not mentioned specifically or
clearly in the trial
Ethnic black Percent of the ethnic population who are black in the trial Percent or NR if not mentioned specifically or
clearly in the trial
Ethnic Hispanic Percent of the ethnic population who are Hispanic in the trial Percent or NR if not mentioned specifically or
clearly in the trial
Ethnic Asian Percent of the ethnic population who are Asian in the trial Percent or NR if not mentioned specifically or
clearly in the trial
Ethnic other Percent of the ethnic population who are other in the trial Percent or NR if not mentioned specifically or
clearly in the trial
Primary disease Primary disease being studied
Percent current smokers Percent of the population who are current smokers Percent or NR if not mentioned specifically or
clearly in the trial
Percent previous smokers Percent of the population who are previous smokers Percent or NR if not mentioned specifically or
clearly in the trial
Percent adenocarcinoma type Percent subjects with NSCLC adenocarcinoma type Percent or NR if not mentioned specifically or
clearly in the trial
Percent squamous cell
carcinoma type
Percent subjects with NSCLC squamous cell carcinoma type Percent or NR if not mentioned specifically or
clearly in the trial
Percent non-squamous
Percent NSCLC stage 0/I/II Percent subjects with NSCLC stage 0 or I or II Percent or NR if not mentioned specifically or
clearly in the trial
Percent NSCLC stage III Percent subjects with NSCLC stage III Percent or NR if not mentioned specifically or
clearly in the trial
Percent NSCLC stage IV Percent subjects with NSCLC stage IV Percent or NR if not mentioned specifically or
clearly in the trial
Percent NSCLC stage III/IV
total
Total percent of subjects with NSCLC stages III or IV Percent or NR if not mentioned specifically or
clearly in the trial
Percent ECOG status 0 Percent subjects with Eastern Cooperative Oncology Group
performance status scale 0
Percent or NR if not mentioned specifically or
clearly in the trial
Percent ECOG status 1 Percent subjects with Eastern Cooperative Oncology Group
performance status scale 1
Percent or NR if not mentioned specifically or
clearly in the trial
Percent ECOG status 0/1 total Percent subjects with Eastern Cooperative Oncology Group
performance status scales 0 or 1
Percent or NR if not mentioned specifically or
clearly in the trial
Percent Karnofsky status ≥80 Percent subjects with Karnofsky’s index of performance status
>80%
Percent or NR if not mentioned specifically or
clearly in the trial
Percent WHO performance
status 0/1
Percent subjects with WHO performance status scale 0 or 1 Percent or NR if not mentioned specifically or
clearly in the trial
Num of metastatic lymph
nodes




Percent subjects who are lymph node positive or with
metastatic lymph nodes
Percent or NR if not mentioned specifically or
clearly in the trial
Percent bone metastasis Percent subjects with bone metastasis Percent or NR if not mentioned specifically or
clearly in the trial
Percent brain metastasis Percent subjects with brain metastasis Percent or NR if not mentioned specifically or
clearly in the trial
Percent liver metastasis Percent subjects with lung metastasis Percent or NR if not mentioned specifically or
clearly in the trial
Percent other metastasis Percent subjects with other metastatic organs Percent or NR if not mentioned specifically or
clearly in the trial
Percent metastatic organ sites 1 Percent subjects with one metastatic organ or site involved Percent or NR if not mentioned specifically or
clearly in the trial
Percent subjects with two metastatic organs or sites involved
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Table 5 Variables for data extraction (Continued)
Percent metastatic organ sites
2
Percent or NR if not mentioned specifically or
clearly in the trial
Percent metastatic organ sites
>3
Percent subjects with three or more metastatic organs or sites
involved
Percent or NR if not mentioned specifically or
clearly in the trial
Percent hemoglobin <11.5 g/
dl
Percent subjects with baseline hemoglobin levels <11.5 g/dl Percent or NR if not mentioned specifically or
clearly in the trial
Patient demographic
comments
Any pertinent demographic comments that are not dealt by
other variables
Any comment that may be relevant to the
understanding of the demographic characteristics
of the patient population
Percent previous surgery Subjects with previous treatment for NSCLC as complete or
partial surgery. Procedures include wedge resection (removal
of part of a lobe), segmentectomy (removal of an anatomic
division of a particular lobe of the lung), lobectomy (one lobe),
bilobectomy (two lobes), or pneumonectomy (whole lung)
Percent or NR if not mentioned specifically or
clearly in the trial
Percent previous radiotherapy Percent subjects with previous radiotherapy as treatment for
NSCLC
Percent or NR if not mentioned specifically or
clearly in the trial
Percent previous
chemotherapy
Percent subjects with previous chemotherapy as treatment for
NSCLC
Percent or NR if not mentioned specifically or
clearly in the trial
Comorbidities At baseline and by treatment arm




Percent subjects with no treatment for NSCLC Percent or NR if not mentioned specifically or
clearly in the trial
Previous treatment comments Comments regarding the previous treatment Any comment that may be relevant to the
understanding of the previous NSCLC treatment in
this record, NA if no comments
Pharmacological therapy information
Repository Description Data entry standards
Primary NSCLC therapy Name of primary drug therapy used in this arm at that time
point
NSCLC drug, e.g., cisplatin, docetaxel
Primary NSCLC dose Randomized daily dose at time of outcome. Please note that
this is the dose the patients were receiving when the
observation is made (not the first randomized dose). If the
treatment is switched at the time of observation, record the
prior treatment the patients were getting just before the
observation was made
Total daily dose at the time of observation
Primary NSCLC dose achieved Average daily dose during assessment period or for the total
treatment period
Average daily dose achieved. Specifically useful for
dose titration and crossover trials, NA for the fixed
dose trials as both dose achieved and total daily
dose do not vary
Primary NSCLC dose unit Unit of total daily or average dose achieved Unit, NR if not reported
Primary NSCLC dose freq/
cycle
Primary Rx days of
administration
e.g., d1, d8
Primary therapy duration and
route of administration
e.g., 10 min i.v. infusion
Primary NSCLC Rx cycle
duration
Primary NSCLC Rx number of
cycles
Primary NSCLC formulation Special treatment formulation Only specialized formulations like IR, CR, SR
Primary NSCLC therapy status Indicates whether the observation refers to the first, continuing
or last dose of the therapy
Start = first dose starts on at this time, continuing =
treatment is continuing at this time, end =
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Table 5 Variables for data extraction (Continued)




Comment regarding the dosing of primary NSCLC treatment Any comment that may be relevant to the
understanding the dosing of the primary treatment
in this record, NA if no comments
Combo NSCLC therapy Name of secondary NSCLC therapy used in this arm in
addition to the primary treatment at that time point
NSCLC drug, e.g., PTH NA if no secondary NSCLC
therapy
Combo NSCLC dose Randomized daily dose of the secondary NSCLC therapy at
time of outcome. Refer to the dose description of primary
NSCLC dose
Total daily dose at the time of observation, NR if




Average daily dose of the secondary NSCLC therapy during
assessment period or for the total treatment period
Average daily dose achieved. Specifically useful for
dose titration and crossover trials, NA for the fixed
dose trials as both dose achieved and total daily
dose do not vary
Combination NSCLC dose unit Unit of total daily or average dose achieved for the secondary
NSCLC therapy
Unit, NR if not reported or NA if no secondary
NSCLC therapy
Combination NSCLC dose reg Frequency of secondary NSCLC therapy being administered QD, BID, etc., NA if no secondary NSCLC therapy
Combination NSCLC dose
freq/cycle
Combination Rx days of
administration
e.g., d1, d8
Combination Rx duration and
route of administration
e.g., 10 min i.v. infusion






Comment regarding the dosing of secondary NSCLC therapy Any comment that may be relevant to the
understanding the dosing of the secondary
treatment in this record, NA if no comments or no
secondary NSCLC therapy
Concomitant medications Baseline or by treatment arm
Radiation therapy information




Repository Description Data entry standards
Assessment Common name for assessment that this record refers to, e.g.,
PANSS
As in the assessments and conventions sheet
Assessment short form Code for the assessment As in the assessments and conventions sheet
Assessment comment Any comment that describes the nature of the assessment e.g., plasma glucose level, NA if no comments
Assessment location Location from where the assessment value is taken or
extracted from the manuscript
Table number, figure number, page number
Assessment category Describes what the assessment value represented is, whether it
is absolute, change from baseline (CFB), percent change from
baseline (PCFB), or fraction of randomized patients with the
event, count in case of tender or swollen joint counts
Absolute, CFB, PCFB, Frac, or Count
Assessment Stat parameter The summary parameter of the assessment value Mean, median, percent, NR if not reported
Stat population Statistical population for which the efficacy/safety analyses
were done and value reported
ITT, OC, completers, randomized, PPP (per protocol
population: define), NR if not reported
Missing data treatment Method used for handling with missing observations in
computing the summary parameter
LOCF (last observation carried forward), none, NR if
not reported and NA in case of completers
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Table 5 Variables for data extraction (Continued)
Scale lower limit Scale lower limit The lower limit of the scale for the assessment, NA
if not applicable




Scale category description Category that is associated with each point of the
scale
Total levels Total categories/points in the scale The total number of categories associated with
each point of the scale, e.g., 0 to 4 point scale
Total symptoms Total symptoms in the scale The total number of symptoms associated with the
respective assessment, NA if not applicable
Total score lower limit Lower limit of the scale, this is calculated as the number of
levels multiplied with the lowest possible scale
Integer value, NA if not applicable
Total score upper limit Upper limit of the scale, this is calculated as the number of
levels multiplied with the highest possible scale
Integer value, NA if not applicable
Assessment level For ordered categorical data “scales.” Indicates which level in
the categorical scale the assessment is referring to
Integer level from 1 to number of levels, if fractional
responder type, enter responder threshold value,
eg., ≥5% weight loss from baseline for total body
weight assessment, etc., NA if not applicable
PROs Scale, mean value, SD by group, time point
Time, assessment, and baseline value information
Repository Description Data entry standards
Assessment visit Clinical visit at which the assessment is done Visit 1 (usually baseline) is the first visit in the active
phase. Lead in visits start at −1 and count
backwards, NR if not reported
Assessment time reported Time at which the assessment is done during the study and as
reported in the manuscript
Visit 1 = baseline = time 0 and the lead in
assessment time starts at −1 and count backwards
Assessment time unit
reported
Unit for reported assessment time Time unit as reported
Assessment time range
reported
In case if the assessment values are average over a time
interval
e.g., weeks 2 through 28 enter 2–28
Assessment time normalized Normalized time in days at which the assessment is done
during the study and as reported in the manuscript
The normalized time value using the normalized
unit as days, e.g., 4 weeks = 28 days
Assessment time unit
normalized
Unit for standard assessment time Days is the standard unit
Assessment value Assessment value reported at that time point Assessment value as reported
Assessment unit Assessment unit as reported Assessment unit as reported, NA if not applicable
Assessment SE SE of reported assessment value SE as reported, NR if not reported




Assessment value normalized Assessment value converted into normalized assessment units Still insert value here, report if normalized units are
the same as the reported units
Assessment value unit norm Normalized assessment value units See assessments and conventions sheet for
normalized assessment standard
Assessment SE normalized Standard error of normalized assessment value SE in the same units as normalized assessment, may
need to be calculated from SD and N; if not
provided, NA
Assessment SD normalized Standard deviation of normalized assessment value SD in the same units as normalized assessment,
may need to be calculated from SE and N; if not
provided, NA
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Assessment number Number of patients assessed at that time point and the value
derived
Integer value, but for responders and dropouts, this
value is calculated from the percentages reported
in the trial
Assessment value comment Comment pertaining to the assessment value that cannot be
dealt by other variables
e.g., the assessment value is the mean of last 7 days
of before each clinical visit, etc.
Hazard ratio 95% confidence intervals, progression-free survival, and overall
survival—adjusted and unadjusted
Baseline visit Clinical visit at which the baseline assessment is done Visit 1 = baseline = time 0, NR if not reported
Baseline time Time at which the baseline assessment is done Visit 1 = baseline = time 0
Baseline time unit Unit for reported baseline time Time unit as reported
Baseline time normalized Normalized time in days at which the baseline is done during
the study and as reported in the manuscript
The normalized time value using the normalized
unit as days, e.g., −4 weeks = −28 days
Baseline time unit normalized Unit for standard baseline time Days is the standard unit
Baseline value Absolute baseline value for that assessment Absolute baseline value
Baseline value unit Assessment unit as reported Assessment unit as reported, NA if not applicable
Baseline SE SE of the absolute baseline value SE as reported, NR if not reported




Baseline value normalized Baseline value converted into normalized baseline units Still insert value here report if normalized units are
the same as the reported units
Baseline value unit normalized Normalized baseline value units See assessments and conventions sheet for
normalized assessment standard
Baseline SE normalized Standard error of normalized baseline value SE in the same units as normalized baseline, may
need to be calculated from SD and N; if not
provided, NA
Baseline SD normalized Standard deviation of normalized baseline value SD in the same units as normalized baseline, may
need to be calculated from SE and N; if not
provided, NA
Baseline CI type normalized
Baseline lower CI normalized
Baseline upper CI normalized
Baseline N Number of patients from which the baseline value is derived Integer
Baseline value comment Comment pertaining to the baseline value that cannot be
dealt by other variables
e.g., the baseline value is the mean of last 7 days of
the run in period
Reference specifications
Repository Description Data entry standards
Ref code Numerical code assigned for the literature citation. Maps the
record to the assessment details
Integer
Protocol or trial number Protocol ID or the number of the trial report As reported, NA if not applicable
Date modified Date of initial entry or subsequent modification of the data
point
mmddyy format
Modified by Initials of curator
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Table 5 Variables for data extraction (Continued)
Modification comment Any comment that is relevant to modification by the curator Initial entry if new record, brief statement of change
(s)
Copyright status Provided by the client or procured by the service provider Client provided or yes in case the manuscript is
procured by the service provider
Author Authors of publication As reported
Journal Journal name Standard abbreviated forms can be used, generally
as in the PubMed
Publication year Year of the publication Integer
Title Title of the study
Volume Volume number of the publication e.g., 180
Pages Page numbers of the publication e.g., 1–24
Trial name alias Trial name that trial is commonly referred to NR if not reported
Inclusion description Provide description of inclusion criteria Can be cut and paste from PDF, can be placed in
an attached note
Exclusion description Provide description of exclusion criteria Can be cut and paste from PDF, can be placed in
an attached note
Study design Brief description of the study design Parallel-fixed arm, dose escalation, effect titration,
crossover, etc.
Location of the trial Geographical location where the study is conducted Primary nationalities list
Number of countries Number of countries the study is conducted Integer
Number of centers Number of centers the study is conducted Integer
Trial start date Date when the trial started mmddyy format
Trial end date Date when the trial completed mmddyy format
Placebo-controlled or active
comparator
Was there a control group and was it placebo PBO control/active comparator





Percent of subjects in the trial who are randomized to placebo Integer
Add-on/washout study Was the study drug added on to standardized background Rx,
was background Rx washed out prior to starting primary Rx, or
was standardized background therapy withdrawn once primary
RX started
Add-On, Washout, Replacement, None
Study blind Was the trial blinded for the treatment phase Yes, double blind
Number of arms Number of treatment arms the patients are randomized to Integer
Arm description Codes and description for arms 0 = placebo and others in sequence
Dose descriptions Brief descriptions of the treatment drugs and the respective
doses along with regimens received
0 = placebo, 1 =metformin 10 mg QW…
Dose ranging within study Does the trial contain at least two primary treatment arms
where different dose strengths were administered
Yes, No. Placebo does not count as a dose strength
Primary longitudinal data Were multiple time values reported for the primary assessment
endpoint
Yes, No.
Active phase trial duration What was the duration of the active phase of the trial Time, units, i.e., 3 weeks
Steady state effect achieved? Does it appear that effect stabilized over time for primary
endpoints
Yes, No. Not clear
Was there a lead-in phase? Was there a standardized lead-in phase in the study other than
a simple screening visit
Yes, No
Lead-in phase duration If so, what was the duration If yes, time, units, i.e., 6 months. If no, 0
Was there a follow-up phase? Was there a standardized follow-up phase that at least some
patients were enrolled in after the active phase ended
Yes, No
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Table 5 Variables for data extraction (Continued)
Duration of follow-up phase If so, what was the duration If yes, time, units, i.e., 6 months. If no, 0






List of the other secondary efficacy or biomarker outcomes
reported in the trial
e.g., HOMA
Most frequent AEs (incidence) List the most frequently reported AE’s e.g., vomiting, nausea, headache, dizziness
Adverse events Grade,%, n by group, treatments for AEs, hospitalizations
secondary to AEs and overall, ICU admissions secondary to AEs
and overall
Median and mean if reported Progression-free survival and overall survival in months (TTPD,
TTTF)
Survival rates Percent alive at X months
Response rates At what time?
Toxicity Number of individuals experiencing toxicity/treatment group
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from models based on direct, indirect, and mixed evi-
dence will be compared. In addition, the heterogeneity
parameters (variance and standard deviation) and good-
ness of model fit measures (residual deviance and devi-
ance information criterion (DIC), a Bayesian criterion
for model comparison) between the direct and indirect
models will be compared.
OS and PFS data will be analyzed using a log trans-
formation of the HR and treating this as a continuous
outcome. For studies with median time information, we
will also use log transformation of the median time and
treat this as a continuous outcome in sensitivity ana-
lyses. HRs are preferred summary statistics to median
time per Michiels and colleagues [13], and hence, the
analysis will utilize HR data for the primary outcome
measure.
Ideally, the literature will provide values for log (HR)
and the standard error (SE) for log (HR). If the SE for
log (HR) is not available, an attempt will be made to es-
timate the missing value from the SE for median time, as-
suming an exponential distribution of survival time
and log (HR) = −log (median time ratio). Alternatively,
an estimate of the SE for log (HR) will be made on
the basis of the number of subjects with events as speci-
fied below:
1. “MedianTime” will be converted into log (median
time);
2. The SE for log (median time) is estimated as (log
(upper confidence limit) − log (lower confidence
limit))/2/quantile (confidence level) if a treatment
arm has non-missing value for all three variables;
3. If confidence limit is missing, then the number of
subjects with events can be used to estimate thestandard error for log (median time) as 1/sqrt(n) for
a treatment arm.
Individual odds ratios and/or toxicity rates for each
grade 3–4 toxicity from each study will be included, re-
spectively, in an NMA using a Bayesian approach that en-
sures the preservation of randomization in the network.
Odds ratios will be calculated for studies reporting toxicity
rates. Prior to creating the odds ratios, we will ensure that
similar versions of toxicity scaling criteria have been used.
Data for analysis will be directly extracted from the text of
the article or calculated from data in the text.
A network meta-analysis of GC +N to all identified
comparators will be conducted for health-related quality
of life (HRQoL) measures (including EQ-5D and the
Lung Cancer Symptom Scale (LCSS)) during and follow-
ing therapy. The most common quality of life instru-
ments as reported across studies will be analyzed. Initial
analyses will be limited to those quality of life outcomes
for which GC +N data are available. For each identified
measure, a standardized mean difference in quality of life
outcomes from each study will be included. First, the
number of trials per HRQoL instrument will be deter-
mined. If the number of trials per HRQoL instrument is 2
or more, then these data will be analyzed. For each instru-
ment, data will be assessed according to the guidelines for
that particular instrument and then pooled across studies
to determine the standardized mean difference.
A meta-regression will be conducted using the key co-
variates of patient age and stage of disease (percent of
patients with stage IV), as these variables have prognos-
tic value in squamous NSCLC. Additional covariates
may be identified following the literature review and will
be considered for inclusion in post hoc analyses to con-
trol for potential bias.
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We anticipate that some studies will not report all rele-
vant data. In order that such studies can still be included
in the analysis, we may consider imputing missing data
using established methods as appropriate [14]. If imput-
ation is made, the Bayesian model as described above
will be used as the primary analysis and will be com-
pared with analyses including the imputed values. Sensi-
tivity analyses may be conducted to examine the effect
of this method using an approach proposed by Carpen-
ter and colleagues [15], which entails imputing missing
data under a missing at random assumption, and then
reweighting the imputed data to allow for non-random
selection. Sensitivity analyses as outlined for OS and PFS
will also be conducted for HRQoL; however, the use of
disparate HRQoL instruments or assessment time points
may result in an inability to evaluate the study endpoint.
Sensitivity analyses will be performed to assess the ro-
bustness of the findings. At a minimum, the following
analyses will be conducted if there are at least three
studies available for analysis:
1. Repeat the meta-analysis using a frequentist
approach;
2. HR only (primary aim) versus HR or median time;
3. By geographical site of study enrollment;a. e.g., Western versus Eastern hemispheres
b. e.g., Americas versus Europe versus Asia
4. Limit to patients with stage IV disease;
5. Direct comparisons only;
6. By excluding phase II trials;
7. By age—studies with a mean age over the age of 70;
8. Limiting the analysis to high-quality studies (≥6) as
determined by the PEDro scale;
9. Removing studies considered to be biased according
to the Cochrane Risk of Bias Tool.
Assessment of bias and study quality
The risk of bias will be appraised using the Cochrane
Risk of Bias Tool (www.cochrane-handbook.org). This
tool was developed specifically to assess the internal val-
idity of RCTs. It consists of the following seven criteria:
1) randomization generation, 2) allocation concealment,
3) blinding of outcome assessors, 4) blinding patients
and personnel, 5) incomplete outcome data (i.e., with-
drawals), 6) selective outcome reporting, and 7) other
risks of bias. The final item will include fraudulent re-
sults, other methodological flaws in the RCTs, and the
potential for bias.
To assess publication bias, the fail-safe N will be calcu-
lated. If the number of unpublished trials that may in-
validate the findings is less than five, it will be noted in
the conclusions as a potential limitation of the findings.
If the number of unpublished trials to invalidate thefindings is five or greater, it will be noted in the results.
Furthermore, funnel plot analyses will also be conducted
to provide a visual representation demonstrating where
unpublished data may exist. This is planned to help
guide the interpretation of the study findings and the
direction of bias.
Quality of selected trials for inclusion in the review
will be assessed. The PEDro quality scale, an 11-item
scale designed for rating the methodological quality of
randomized controlled trials [16], will be used to evalu-
ate the quality of selected trials. Here the two reviewers
will independently assess studies for methodological val-
idity prior to inclusion. Identified studies that meet the
inclusion criteria will then be grouped according to the
class of statin used in the trial. High quality scores will
be defined as a PEDro score ≥6 and low quality scores
will be defined as a PEDro score <6.
Missing data are expected in the majority of data fields
collected in this meta-analysis. In cases of missing data, het-
erogeneity will be tested on all outcome variables to ensure
that studies are comparable. Forest plots will be created for
OS, PFS, toxicity, and quality of life endpoints. In the case
of non-overlapping confidence intervals, the research team
will discuss the need for post hoc subgroup analyses.
Discussion
The study design for this systematic review and meta-
analysis is presented here to follow PRISMA standards.
Industry-sponsored or industry-led studies are increas-
ingly under scrutiny regarding transparency and risk of
bias [17]. This study protocol has been designed prior to
any knowledge of the study data or outcomes from exist-
ing published literature and is being disseminated in an at-
tempt to provide the scientific community with the ability
to evaluate the methods and plans of our study before it is
conducted. The study protocol has been designed to meet
PRISMA standards [18,19] and is being disclosed so that
our methods can be retrieved and evaluated against the
final analyses and interpretation of findings.
While it is almost impossible to fully anticipate the limi-
tations of the data once they are obtained, this study has
been designed in an attempt to pre-specify all primary ana-
lyses and sensitivity analyses to demonstrate the stability in
results that may be discovered. However, it is possible that
there will not be sufficient data to achieve all the pre-
specified study aims or to complete all planned analyses.
There are also possible limitations in the network connec-
tions. Unlike patients diagnosed with lung cancers of non-
squamous histology, those with squamous NSCLC have
not benefited from the same depth and breadth of research
conducted to identify optimal treatment strategies. There-
fore, via our search criteria, we are casting a wide net in
the hopes of finding studies that not only investigate, but
also report, outcomes for this histological subgroup.
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data regarding the comparative efficacy of necitumumab
against other possible options for care so that decision
makers can come to their own conclusions regarding the
value of this molecule currently in development.
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